• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

    7/15/24 12:05:30 PM ET
    $AMIX
    $ASLN
    $DJT
    $LXEO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMIX alert in real time by email

    U.S. stocks traded higher midway through trading, with the Nasdaq Composite rising more than 200 points on Monday.

    The Dow traded up 0.73% to 40,291.69 while the NASDAQ rose 1.16% to 18,611.47. The S&P 500 also rose, gaining, 0.81% to 5,660.67.

    Check This Out: Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying

    Leading and Lagging Sectors

    Energy shares jumped by 1.6% on Monday.

    In trading on Monday, utilities shares fell by 2.1%.

    Top Headline

    The NY Empire State Manufacturing Index fell to a reading of -6.6 in July, compared to market estimates of -6.

    Equities Trading UP
                           

    • Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) shares shot up 51% to $6.12 after the company announced in-vivo preclinical study results of NanoAb.
    • Shares of Autonomix Medical, Inc. (NASDAQ:AMIX) got a boost, surging 149% to $1.48 after the company entered into an agreement with RF Innovations to license intellectual property for its Apex 6 Radiofrequency Generator.
    • Trump Media & Technology Group Corp. (NASDAQ:DJT) shares were also up, gaining 29% to $39.98 following the attempted assassination of Donald Trump.

    Equities Trading DOWN

    • ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) shares dropped 44% to $1.40 after the company announced receipt of Nasdaq delisting determination.
    • Shares of Catheter Precision, Inc. (NYSE:VTAK) were down 18% to $3.15. Catheter Precision announced effectiveness of 1-for-10 reverse stock split.
    • Lexeo Therapeutics, Inc (NASDAQ:LXEO) was down, falling 24% to $13.31 after the company reported interim data of LX2006 for the treatment of Friedreich ataxia cardiomyopathy.

    Also Check This Out: This Analyst With 87% Accuracy Rate Sees More Than 12% Upside In AMD – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts

    Commodities

    In commodity news, oil traded down 0.2% to $82.08 while gold traded up 0.8% at $2,439.10.

    Silver traded up 0.3% to $31.26 on Monday, while copper fell 1% to $4.5475.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 fell 0.91, Germany's DAX fell 0.69% and France's CAC 40 fell 1.16%. Spain's IBEX 35 Index fell 0.79%, while London's FTSE 100 fell 0.75%.

    Industrial production in the Eurozone declined 0.6% month-over-month in May following a flat reading in the prior month.

    Asia Pacific Markets

    Asian markets closed mixed on Monday, with Hong Kong's Hang Seng Index falling 1.52%, China's Shanghai Composite Index gaining 0.09% and India's S&P BSE Sensex gaining 0.18%.

    Indian merchandise trade deficit increased to $21 billion in June from $20.1 billion in the year-ago period, while wholesale prices rose by 3.36% year-over-year in June following a 2.61% increase in the prior month. Total passenger vehicle sales in India surged 5.0% year-over-year to 294,133 in June.

    Chinese retail sales increased by 2% year-over-year in June, while industrial production climbed by 5.3% year-over-year in June. The Chinese economy expanded by 0.7% in the second quarter, compared to a revised 1.5% increase in the prior quarter.

    Economics

    The NY Empire State Manufacturing Index fell to a reading of -6.6 in July, compared to market estimates of -6.

    Now Read This: Top 5 Financials Stocks That May Collapse This Month

    Get the next $AMIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMIX
    $ASLN
    $DJT
    $LXEO

    CompanyDatePrice TargetRatingAnalyst
    Lexeo Therapeutics Inc.
    $LXEO
    12/18/2025$25.00Strong Buy
    Raymond James
    Lexeo Therapeutics Inc.
    $LXEO
    11/20/2025$19.00Overweight
    Cantor Fitzgerald
    Lexeo Therapeutics Inc.
    $LXEO
    10/15/2025$30.00Buy
    Guggenheim
    Lexeo Therapeutics Inc.
    $LXEO
    7/31/2025$20.00Outperform
    Oppenheimer
    Lexeo Therapeutics Inc.
    $LXEO
    6/13/2024$28.00Outperform
    Robert W. Baird
    Lexeo Therapeutics Inc.
    $LXEO
    6/6/2024$22.00Buy
    H.C. Wainwright
    Lexeo Therapeutics Inc.
    $LXEO
    11/28/2023$20.00Overweight
    JP Morgan
    Lexeo Therapeutics Inc.
    $LXEO
    11/28/2023$20.00Buy
    Stifel
    More analyst ratings

    $AMIX
    $ASLN
    $DJT
    $LXEO
    SEC Filings

    View All

    SEC Form 144 filed by Lexeo Therapeutics Inc.

    144 - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    2/18/26 3:28:10 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    2/17/26 4:38:17 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    2/17/26 4:02:14 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMIX
    $ASLN
    $DJT
    $LXEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel and Secretary Glabe Scott bought $10,465 worth of shares (1,000 units at $10.46), increasing direct ownership by 0.31% to 326,236 units (SEC Form 4)

    4 - Trump Media & Technology Group Corp. (0001849635) (Issuer)

    11/19/25 8:48:25 PM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    Director Cholmondeley Paula H bought $104,852 worth of shares (15,000 units at $6.99), increasing direct ownership by 96% to 30,627 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    11/26/24 5:00:06 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMIX
    $ASLN
    $DJT
    $LXEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Bhalla Narinder Pal was granted 49,500 shares (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    2/17/26 4:55:06 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Tamayo Louis Edward was granted 44,665 shares, increasing direct ownership by 99% to 89,665 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    2/6/26 5:00:09 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Townsend Richard Nolan was granted 161,665 shares, increasing direct ownership by 67% to 402,656 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    2/6/26 5:00:12 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMIX
    $ASLN
    $DJT
    $LXEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    VTAK Acquires 19.98% Strategic Stake in AI-Enabled Aviation Company Fly Flyte, Inc.

    Immediate Exposure to Revenue-Generating, Asset-Backed Regional Air Mobility Business Positioned Ahead of Anticipated Future Industry-wide eVTOL Commercialization Strategic Investment Expands Capital Allocation into High-Growth Infrastructure with Scalable Fleet Expansion and Long-Term Equity Upside Fort Mill, S.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced a strategic minority investment in Fly Flyte, Inc. ("Flyte"), an FAA-certified regional aviation operator utilizing AI-enabled operations and a growing fleet of Cirrus Vision Jets. Flyte conducts its flight operations through its wholly owned subsidiary, Ponderosa Air, LLC (FAA Air Carrie

    2/17/26 7:45:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

    JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today announced that it has acquired 100% of the shares of Recipharm Israel Ltd., which operates Recipharm's site in Yavne, Israel, and entered into a long-term strategic commercial collaboration with Recipharm. The transactions significantly expand Scinai's manufacturing footprint, capabilities, and commercial positioning, strengthening its

    2/17/26 7:00:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMIX
    $ASLN
    $DJT
    $LXEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Lexeo Therapeutics with a new price target

    Raymond James initiated coverage of Lexeo Therapeutics with a rating of Strong Buy and set a new price target of $25.00

    12/18/25 9:11:03 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Lexeo Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $19.00

    11/20/25 8:07:20 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Lexeo Therapeutics with a new price target

    Guggenheim initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $30.00

    10/15/25 8:29:39 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMIX
    $ASLN
    $DJT
    $LXEO
    Financials

    Live finance-specific insights

    View All

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    Trump Media & Technology Group to Merge with TAE Technologies, a Premier Fusion Power Company, in All-Stock Transaction Valued at More Than $6 Billion

    Combined company expects to site and commence construction of the first utility-scale fusion power plant in 2026  Fusion power to blaze path toward America's A.I. dominance and energy security Conference call scheduled for 9 a.m. ET, December 18, 2025   SARASOTA, Fla. and FOOTHILL RANCH, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Trump Media & Technology Group Corp. (Nasdaq, NYSE Texas: DJT) ("TMTG") and TAE Technologies, Inc. ("TAE") today announced the signing of a definitive merger agreement to combine in an all-stock transaction valued at more than $6 billion. Upon closing, shareholders of each company will own approximately 50% of the combined company on a fully diluted equity basis

    12/18/25 6:30:00 AM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    $AMIX
    $ASLN
    $DJT
    $LXEO
    Leadership Updates

    Live Leadership Updates

    View All

    Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

    NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a series of key senior leadership appointments that underscore the company's continued and growing expertise in cardiovascular medicine and late-stage clinical development. The company also provided an update on the strategic partnership announced in June 2025 with Perceptive Xontogeny Venture Funds and venBio Partners to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform. Narinder Bhalla, MD has been appointed Chief Medical Officer, effective

    1/27/26 7:30:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

    Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)PC111 has already received an Orphan Drug Designation in Pemphigus by the European Medicine's AgencyAn application will be filed with the FDA for Orphan Drug and Breakthrough Designation in Pemphigus, as well as in SJS/TENScinai sees potential for accelerated approval given the severity of these diseases, PC111's innovative, non-immunosuppressive mode of action and the lack of effective alternative treatmentsJERUSALEM, March 27, 2025 /PRNewswire/ -- Scinai Imm

    3/27/25 9:25:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Trump Media Announces Intention to Partner with Crypto.com to Launch ETFs

    America-First Investment Funds Slated to Launch in 2025 SARASOTA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Trump Media and Technology Group Corp. (NASDAQ:DJT) ("TMTG" or the "Company"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, has signed a non-binding agreement to partner with Crypto.com, America's premier crypto trading platform, to launch a series of exchange-traded funds and exchange-traded products (collectively, "ETFs") through the Truth.Fi brand. The ETFs, made available through Crypto.com's broker dealer Foris Capital US LLC, are expected to comprise digital assets as well as securities with a Made in Americ

    3/24/25 5:00:00 PM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    $AMIX
    $ASLN
    $DJT
    $LXEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    12/3/24 6:17:58 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    11/27/24 10:15:18 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Trump Media & Technology Group Corp.

    SC 13G/A - Trump Media & Technology Group Corp. (0001849635) (Subject)

    11/14/24 9:53:48 PM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology